• June’s top stories: Bayer reported positive results of RESORCE trial, TapImmune initiated Phase II trial of TPIV 200

  Bayer reported positive results from the Phase III RESORCE trial of Stivarga (regorafenib) tablets to treat unresectable hepatocellular carcinoma, and TapImmune initiated its Phase II trial of cancer vaccine TPIV...

• May’s top stories: ProMedica began human stem cell trial, Cerulean dosed in Phase l/ll combination trial

  ProMedica and Stemedica planned to begin a human stem cell trial for traumatic brain injury and Cerulean dosed its first patient in a Phase l/ll combination trial of CRLX101 and...

• April’s top stories: SynbiCITE’s synthetic biology foundry, Omeros’s phase II clinical trial of OMS721

  SynbiCITE opened a commercial synthetic biology foundry at Imperial College London, and Omeros began dosing patients in its new Phase ll clinical trial of OMS721 in corticosteroid-dependent renal diseases. Drugdevelopment-technology.com...

• March’s top stories: Tracon’s Phase IbTRC105 clinical trial, ADC begins ADCT-402 trial

  Tracon Pharmaceuticals started Phase Ib clinical trial of TRC105, a clinical stage antibody to endoglin, and ADC Therapeutics began a Phase I trial of its antibody drug conjugate (ADC) ADCT-402....

• Pharma Technology Focus – Issue 45

  In this issue: Israel’s pharma market, what Brexit would mean for clinical research in the UK, developments in obstetrics, the trouble with inhalable insulin, the FDA’s new support for innovation...

• February’s top stories: 60% of trial results not shared, Dilaforette-AGU team-up

  Yale School of Medicine researchers revealed about 60% of academic clinical trial results were not shared after completion, and Dilaforette and Arabian Gulf University were to collaborate on a Phase...

• Pharma Technology Focus – Issue 44

  In this issue: Clinical trials in Russia, how understanding the microbiome could help with drug delivery, making the most of data analytics, the potential of wearable trackers in clinical trial...

• January’s top stories: Profectus Ebola trial, AstraZeneca-Incyte lung cancer drug

  Profectus BioSciences began VesiculoVax-vectored vaccine trial, AstraZeneca and Incyte announced combination drug evaluation, SillaJen started Phase III trial for Pexa-Vec. Drugdevelopment-technology.com wraps-up the key headlines from January.

• Pharma Technology Focus – Issue 43

  In this issue: A look inside China’s pharmaceutical market, GSK’s pipeline to 2020, tackling the world’s most pressing clinical needs, new digital tools for clinical trials, a new approach to...

• 2015: The year’s biggest Drug Development Technology stories

  UK develops method to improve drug delivery in cancer treatment, skin cancer drug trial starts in UK, and Nestlé and EpiGen to assess impact of nutrients during pregnancy. Drug Development-technology.com...